Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|February 7, 2014

Shimadzu Opens New Solution Center in Maryland

Shimadzu's new Solution Center features additional research space.

Shimadzu Scientific Instruments

has opened its new Shimadzu Solution Center at its headquarters in Columbia, MD. The new 4100 ft

2

facility provides additional research space to more efficiently develop new software applications. The center also features video and conferencing equipment to facilitate customer interactions both within the center and in collaboration with manufacturing, software, and R&D groups.

Source:

Shimadzu Scientific Instruments


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.